Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEGACY: Omitting Aspirin in NSTE-ACS Patients
NCT05125276Phase 4Unknown
- Sponsor
- University of Amsterdam
- Start
- May 2022
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) (2 arms), sponsored by University of Amsterdam. Primary endpoints: Major or minor bleeding at 12 months and Composite of all-cause death, myocardial infarction and stroke at 12 months. Status: unknown.
02
Drugs
aspirin
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT05125276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125276.